Vivjoa™(oteseconazole) – New drug approval
April 28, 2022 - Mycovia Pharmaceuticals announced the FDA approval of Vivjoa (oteseconazole) to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Download PDF
